雅虎香港 搜尋

登入

搜尋結果

  1. www.sanofi.com › assets › countriesPROFESSIONAL INFORMATION FOR VAXIGRIP TETRA - Sanofi

    VAXIGRIP TETRA is indicated for the prevention of influenza disease caused by the two influenza. virus subtypes and the two influenza B virus types contained in the vaccine for: active immunisation of adults, including pregnant women, and children from 6 months of age. and older,

  2. www.chp.gov.hk › tc › features衞生防護中心 - 2024-25 季度本港季節性流感疫苗接種 ...

    如採用雞胚生產的三價流感疫苗，當中的乙型流感成分應包括類乙型/奧地利/1359417/2021 (B/Victoria譜系) 病毒。. 「疫苗可預防疾病科學委員會」建議在 2024-25 季度使用以細胞培養或重組技術生產的四價疫苗包括以下成分︰. 類甲型/威斯康辛/67/2022 (H1N1)pdm09病毒. 類甲 ...

  3. www.news-medical.net › drugs › Vaxigrip-TetraVaxigrip Tetra Drug / Medicine Information - News-Medical.ne ...

    5 天前 · Vaxigrip Tetra is a vaccine. This vaccine helps to protect you or your child against influenza (flu). Vaxigrip Tetra is used to prevent flu in persons of 6 months of age and older. If you are...

  4. www.sanofi.com › docs › Vaxigriptetra---NH23-24--SG-05232. QUALITATIVE AND QUANTITATIVE COMPOSITION - Sanofi

    Therapeutic indications. VaxigripTetra is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for: - active immunisation of adults, including pregnant women, and children from 6 months of age.

  5. www.drugoffice.gov.hk › eps › drugPHARMACY & POISONS BOARD OF HONG KONG | 香港藥劑業及毒藥 ...

    2024年10月4日 · VAXIGRIPTETRA VACCINE 0.5ML Registration No.: HK-65577 Certificate Holder: SANOFI HONG KONG LIMITED Certificate Holder Address:

  6. health.udn.com › health › pharma菲流達四價流感疫苗的功效、適應症及副作用｜元氣網

    2022年9月2日 · VAXIGRIPTETRA適用於成人及6個月(含)以上兒童之主動免疫接種，預防此疫苗所涵蓋之兩種A型及兩種B型流感病毒所引起的流感相關疾病。 相關疾病說明: 小兒麻痺 玫瑰疹 德國麻疹 雷氏症候群 百日咳

  7. pubmed.ncbi.nlm.nih.gov › 29157068Quadrivalent inactivated influenza vaccine (VaxigripTetra&tr ...

    VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).